Muaiad Kittaneh, Global Head of RandD and Scintific Strategy at Syneos Health, shared a post by Syneos Health on LinkedIn, adding:
“Excited to be part of this upcoming discussion on MRD-driven oncology trials with an outstanding group of colleagues at Syneos Health (Wael Harb, Zohra Lomri, Pierre-Olivier T.) and Dr Rafat Abonour.
Minimal residual disease is increasingly shaping how we think about early-phase development, dose optimization, and ultimately regulatory strategy. As we move toward more precise and efficient trial designs, integrating MRD is no longer optional, it is becoming foundational.
In this webinar, we will focus on practical considerations:
- How to incorporate MRD into early and registrational studies
- Aligning MRD endpoints with regulatory expectations
- Translating biomarker insights into actionable development decisions
Looking forward to sharing perspectives and engaging with others working at the intersection of clinical development and biomarker-driven innovation.
May 6, 2026 | 11:00 AM ET
Registration link in the original post.”
Quoting Syneos Health’s post:
“Minimal residual disease is rapidly becoming a defining factor in how oncology programs are designed, evaluated and accelerated.
The discussion in this upcoming Xtalks webinar will cover how to integrate MRD across early-phase and registrational studies, align with regulatory expectations and address real-world execution challenges.
Join Syneos Health experts Wael Harb, Zohra Lomri, Pierre-Olivier T., Muaiad Kittaneh and Rafat Abonour as they share practical perspectives on incorporating MRD into development strategy, from dose selection and cohort expansion to regulatory positioning and evidence generation.”
Other Articles Featuring Muaiad Kittaneh on OncoDaily.